To facilitate manufacturer understanding of the Preliminary Rebate Report, CMS is proposing in proposed 428.401(b)(1) that the Preliminary Rebate Report would include the following information: the NDC(s) for the Part D rebatable drug as defined under proposed 428.20
J7500: Azathioprine (Imuran) for Lupus, Crohn's, Sjgren's
The health risks of using nicotine include everything from increased blood pressure to increased heart rate, increased heart attack risk and a narrowing of the arteries, research shows
To identify the payment amount benchmark period for a Part D rebatable drug, CMS would use the FDA approval date or the first marketed date reported under section 1927(b)(3)(A)(v) of the Act, as applicable
Additionally, the studies did not control for other types of interventions deployed in the treatment of diabetes (that is, strategies used to manage glycemic control), so patients may have been receiving other types of treatment during the study periods
and the NIH Distinguished Scholars Program, designed to promote and enhance DEIA within the NIH intramural program (864)
